lonafarnib has been researched along with manumycin in 3 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (manumycin) | Trials (manumycin) | Recent Studies (post-2010) (manumycin) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 159 | 0 | 47 |
| Protein | Taxonomy | lonafarnib (IC50) | manumycin (IC50) |
|---|---|---|---|
| Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus (Norway rat) | 0.81 | |
| GTPase KRas | Homo sapiens (human) | 3.58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
| Chen, B; Lee, MH; Pan, J; Su, CH; Sun, L; Xu, ZX; Yeung, SC; Zhao, R | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
1 review(s) available for lonafarnib and manumycin
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
2 other study(ies) available for lonafarnib and manumycin
| Article | Year |
|---|---|
Autophagy induced by farnesyltransferase inhibitors in cancer cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Pancreatic Neoplasms; Piperidines; Polyenes; Polyunsaturated Alkamides; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2008 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |